Nevertheless, certain tumor types, such as colon, lung cancer, and pancreatic tumor, remain characterized by poor responsiveness to anti‐PD‐1 immunotherapy.[21] To evaluate whether STK24 deficiency synergizes with immune checkpoint blockade therapy, the anti‐PD‐1 mAb or the anti‐IgG mAb was i.p. injected into the immune‐competent mice inoculated with STK24 knockout tumor cells (Stk24 KO) or the wild‐type control (Ctrl) (Figure 6A–F). This evidence concerns the gene PDCD1 and pancreatic neoplasm.